Marquette Asset Management LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) by 89.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 47,166 shares of the company’s stock after purchasing an additional 22,301 shares during the period. Marquette […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript February 28, 2024 Atea Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Fourth Quarter 2023 Financial Results and Business Update […]
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) CEO Jean-Pierre Sommadossi sold 56,910 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $3.85, for a total value of $219,103.50. Following the sale, the chief executive officer now owns 116,557 shares of the company’s […]
Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions].
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2023 Earnings Call Transcript November 8, 2023 Atea Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.4, expectations were $-0.46. Operator: Good afternoon, ladies and gentlemen. Welcome to the Atea Pharmaceuticals Third Quarter 2023 Financial Results and Business Update Conference Call. [Operator Instructions]. I would now like to turn the […]